Dashboard
Manage Tickers

MORMorphoSys AG

Nasdaq morphosys.com


$ 17.96 $ 0.02 (0.11 %)    

Wednesday, 08-May-2024 15:59:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 17.96
$ 17.92
$ 0.00 x 0
$ 0.00 x 0
$ 17.92 - $ 17.97
$ 4.19 - $ 18.31
318,797
na
676.29M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

morphosys-group-ag-anticipates-close-of-proposed-acquisition-by-novartis-in-h1-2024-submit-a-new-drug-application-for-pelabresib-in-combination-with-ruxolitinib-in-myelofibrosis-to-fda-and-marketing-authorization-application-to-european-medicines-agency-in-h2-2024
Morphosys Group Ag Anticipates Close Of Pr...
04/29/2024 20:22:45

morphosys-group-ag-q1-2024-eps-927-down-from-094-yoy-revenue-275m-up-from-243m-yoy
MorphoSys Group AG Q1 2024 EPS €(9.27) Dow...
04/29/2024 20:14:22

morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer-drug-pelabresib
MorphoSys Says Novartis Deal Progressing S...
04/29/2024 16:36:10

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to...

incyte-should-consider-significant-stock-buyback-and-prioritize-rd-analyst-recommends
Incyte Should Consider Significant Stock B...
04/23/2024 19:03:10

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a ...

Core News & Articles
MorphoSys AG Form SC TO-T/Amended Shows No...
04/15/2024 19:55:01

On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeove...

morphosys-management-board-and-supervisory-board-recommend-shareholders-accept-public-takeover-offer-by-novartis-for-6800-per-share-in-cash
MorphoSys' Management Board And Supervisor...
04/11/2024 13:09:37

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attracti...

Core News & Articles
Novartis Tender Offer For Morphosys Comme...
04/11/2024 08:52:50

Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis Bid...

morphosys-bags-us-antitrust-clearance-of-proposed-acquisition-by-novartis-under-hsr-act
MorphoSys Bags US Antitrust Clearance of P...
03/22/2024 07:04:21

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrus...

wells-fargo-downgrades-morphosys-to-equal-weight-raises-price-target-to-1825
Wells Fargo Downgrades MorphoSys to Equal-...
03/14/2024 20:07:04

Wells Fargo analyst Derek Archila downgrades MorphoSys (NASDAQ:MOR) from Overweight to Equal-Weight and raises the price tar...

morphosys-q4-earnings-insights
MorphoSys: Q4 Earnings Insights
03/13/2024 20:20:23

morphosys-q4-eps-033-beats-009-estimate-sales-6351m-miss-6789m-estimate
MorphoSys Q4 EPS $0.33 Beats $0.09 Estimat...
03/13/2024 20:16:26

MorphoSys (NASDAQ:MOR) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.09 by 266...

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

earnings-outlook-for-morphosys
Earnings Outlook For MorphoSys
03/12/2024 15:02:28

Core News & Articles
MorphoSys Spokesperson Says "This Story Is...
02/06/2024 18:49:01

Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com) Novartis said Monday that it intends to buy Morp...

novartis-agrees-to-acquire-german-blood-cancer-drug-developer-morphosys-for-27b
Novartis Agrees To Acquire German Blood Ca...
02/06/2024 13:46:05

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tul...

Core News & Articles
MorphoSys Enters Into Business Combination...
02/05/2024 21:53:17

https://www.eqs-news.com/company/morphosys-ag/news/5b719341-ea7c-11e8-902f-2c44fd856d8cMorphoSys Enters into Business Combinati...

Core News & Articles
Incyte Enters Asset Purchase Agreement Wit...
02/05/2024 21:48:42

Incyte gains exclusive global rights for tafasitamab, a humanized Fc-modifiedCD19-targeting immunotherapy marketed in the U.S. ...

wells-fargo-reiterates-overweight-on-morphosys-maintains-17-price-target
Wells Fargo Reiterates Overweight on Morph...
02/05/2024 19:16:53

Wells Fargo analyst Derek Archila reiterates MorphoSys (NASDAQ:MOR) with a Overweight and maintains $17 price target.

why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Air Products and Chemicals Shares Are ...
02/05/2024 17:56:50

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-th...

morphosys-stock-soars-after-report-says-novartis-to-acquire-cancer-drug-developer
MorphoSys Stock Soars After Report Says No...
02/05/2024 17:31:10

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION